Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025
09:34am, Friday, 11'th Jul 2025
This isn't a buy list. It's a shortlist to help you speed up your research. We've included both U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull a
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
03:55am, Friday, 11'th Jul 2025
Dividend investing, like most things in life, can be rewarding if done correctly or a headache if you make crucial mistakes. The key to dividend investing is to pick the right types of dividend stocks
Glenmark Pharma jumps on unit's cancer licensing deal with AbbVie
11:55pm, Thursday, 10'th Jul 2025
Shares of Glenmark Pharmaceuticals jumped 10% in early trade on Friday, a day after a unit of the Indian drugmaker signed an exclusive licensing deal with U.S. peer AbbVie for its cancer treatment.
AbbVie (ABBV) Laps the Stock Market: Here's Why
06:46pm, Thursday, 10'th Jul 2025
AbbVie (ABBV) closed the most recent trading day at $195, moving +2.3% from the previous trading session.
Why Is AbbVie Stock Trading Higher On Thursday?
02:36pm, Thursday, 10'th Jul 2025
IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. ABBV, on Thursday, announced an exclusive licensing agreement for IGI's lead investiga
Final Trades: Abbvie, Boeing, Oracle and Joby Aviation
02:03pm, Thursday, 10'th Jul 2025
The Investment Committee give you their top stocks to watch for the second half.
India's Glenmark Pharma unit, Abbvie sign exclusive licensing pact
07:44am, Thursday, 10'th Jul 2025
India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have signed an exclusive global licensing agreement for IGI's cancer treatment, ISB 2
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NORTH CHICAGO, Ill. and NEW YORK , July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
01:41pm, Tuesday, 08'th Jul 2025
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
09:31am, Tuesday, 08'th Jul 2025
ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Monday, 07'th Jul 2025
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 ETFs To Prepare You For A Potential Recession
06:50am, Monday, 07'th Jul 2025
I see a 50-60% chance of a recession in the next 12–24 months, so portfolio preparation is essential. I recommend the iShares Gold Trust Micro as a low-cost gold ETF that has outperformed during rec
3 No-Brainer Stocks to Buy in July
06:40am, Monday, 07'th Jul 2025
Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.
2 Dividend Stocks to Buy for Decades of Passive Income
08:45am, Sunday, 06'th Jul 2025
In 2013, AbbVie (ABBV -0.93%) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (ABT 0.18%). Since then, both have produced strong returns and ha
